PHARMAC - Latest News [Page 1]

Independent Review Of Lamotrigine Sole Supply Decision By PHARMAC

Friday, 5 June 2020, 10:11 am | PHARMAC

An independent review on the lamotrigine sole-supply decision has found that PHARMAC’s processes were evidence based and robust, and of a high standard. The review was published on the PHARMAC website today and shared with people who had been engaging ... More >>

PHARMAC To Fund New Cystic Fibrosis Medicine

Saturday, 30 May 2020, 8:35 am | PHARMAC

From Monday a new medicine is being funded by PHARMAC which will help young children with cystic fibrosis digest their food more easily. Creon Micro, supplied by Mylan, is a modified-release granule formulation of pancreatic enzymes. It enables smaller ... More >>

PHARMAC Places Temporary Dispensing Limits On All Funded Community Medicines

Thursday, 26 March 2020, 1:30 pm | PHARMAC

PHARMAC is placing temporary dispensing limits on all funded community medicines from Friday 27 March 2020. Changes will be made to the Pharmaceutical Schedule, which is a list of the prescription medicines and therapeutic products subsidised by the ... More >>

PHARMAC Funds New Medicine (mepolizumab) For Severe Asthma

Thursday, 12 March 2020, 12:42 pm | PHARMAC

Around 500 New Zealanders who have severe asthma will have access to a new medicine, mepolizumab, from next month. Severe asthma sufferers who use mepolizumab are less likely to end up in hospital and less likely to experience their symptoms getting ... More >>

PHARMAC seeking views on new cystic fibrosis medicine

Friday, 24 January 2020, 1:01 pm | PHARMAC

PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund ivacaftor (marketed as Kalydeco) for people with cystic fibrosis. More >>

PHARMAC considering new medicines for type 2 diabetes

Wednesday, 15 January 2020, 4:44 pm | PHARMAC

PHARMAC is seeking proposals from pharmaceutical suppliers for new medicines that could help New Zealanders living with type 2 diabetes. More >>

PHARMAC seeking views on new breast cancer medicine

Wednesday, 15 January 2020, 10:01 am | PHARMAC

PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) for first-line and second-line treatment of certain types of breast cancer. More >>

Spinraza funding application reviewed

Tuesday, 17 December 2019, 9:28 am | PHARMAC

PHARMAC has published the Rare Disorders Subcommittee meeting records which recommends Spinraza (nusinersen), a medication for spinal muscular atrophy, is funded in New Zealand. More >>

PHARMAC to fund more cancer medicines and faster assessment

Thursday, 5 December 2019, 9:09 am | PHARMAC

Thousands of New Zealanders with lymphoma, breast, ovarian and blood cancers will have more treatment options available to them in the New Year. More >>

PHARMAC widening access to the meningococcal ACWY vaccine

Thursday, 14 November 2019, 9:38 am | PHARMAC

The meningococcal ACWY vaccine will be available free from next month for young people in close living situations. More >>

PHARMAC funding new leukaemia medicine

Monday, 4 November 2019, 10:19 am | PHARMAC

New Zealanders with chronic lymphocytic leukaemia will have another medicine option available to help them live longer from 1 December 2019. More >>

21,000 to benefit from Mirena and Jaydess

Monday, 14 October 2019, 9:27 am | PHARMAC

PHARMAC is widening funded access to Mirena, as well as listing a new long-acting reversible contraceptive option, Jaydess, which will benefit around 21,000 New Zealand women. More >>

PHARMAC signs bundle deal for more cancer medicines

Monday, 7 October 2019, 1:41 pm | PHARMAC

420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier. More >>

Lamotrigine brand change from today

Tuesday, 1 October 2019, 12:42 pm | PHARMAC

From today there will be one funded brand of lamotrigine - a medicine used to treat epilepsy and some mental health conditions, including bipolar disorder. More >>

PHARMAC says more medicines on the way

Sunday, 1 September 2019, 3:47 pm | PHARMAC

PHARMAC says more medicines on the way PHARMAC has reached a deal with pharmaceutical companies for three new medicines to treat ovarian cancer, breast cancer and leukaemia. “The $60 million boost means we can make real inroads into funding medicines on ... More >>

Influenza vaccination levels hit near record levels

Thursday, 6 June 2019, 4:04 pm | PHARMAC

Director of Operations of Lisa Williams said this was the highest number of vaccines to have been distributed so early in winter. More >>

1500 New Zealanders access a cure for hepatitis C

Tuesday, 28 May 2019, 11:17 am | PHARMAC

Over 1500 New Zealanders have started a new hepatitis C treatment in the last three months that could dramatically change their lives. More >>

PHARMAC fully funding innovation in haemophilia treatment

Wednesday, 1 May 2019, 1:07 pm | PHARMAC

PHARMAC has today provided haemophilia patients fully funded access to new innovative treatment options which will make a major difference to their lives, PHARMAC Director of Operations Lisa Williams says. More >>

PHARMAC to give more clarity about funding decisions

Tuesday, 30 April 2019, 9:53 am | PHARMAC

An overhaul of PHARMAC’s decision-making process will give better insight into what medicines are - and are not - being actively considered for funding, Chief Executive, Sarah Fitt says. More >>

PHARMAC funds potential Hepatitis C cure

Monday, 17 December 2018, 1:02 pm | PHARMAC

Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February 2019, after PHARMAC funds a new treatment. The medicine known as Maviret (glecaprevir and pibrentasvir) can be prescribed to people with hepatitis ... More >>